Library Subscription: Guest
International Journal of Medicinal Mushrooms

Published 12 issues per year

ISSN Print: 1521-9437

ISSN Online: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease

Volume 6, Issue 4, 2004, 8 pages
DOI: 10.1615/IntJMedMushr.v6.i4.30
Get accessGet access

ABSTRACT

The polysaccharides and triterpenes isolated from Ganoderma lucidum have shown hypolipidemic, hypotensive, and antithrombotic effects. This double-blind, randomized, multicentered study was designed to evaluate the clinical effects and safety of extracted G. lucidum polysaccharides (Ganopoly) in patients with confirmed coronary heart disease (CHD). Patients were randomly assigned to receive Ganopoly (n = 88) or placebo (n = 82) for 12 weeks. Effects of therapy on improvement of major symptoms, electrocardiogram (ECG) changes, and serum cholesterol level were investigated. Ten patients were lost to the trial, leaving 80 in each group to be assessed after 12 weeks. The results indicate that patients in both groups were similar with respect to age, gender, serum cholesterol level, and disease duration. Ganopoly treatment gave a significantly higher improved percentage (31.6−54.7%) of the primary symptoms (chest pain, palpitation, angina pectoris, and shortness of breath) in CHD patients compared to the control group (17.2−24.7%). The percentage of abnormal ECG also significantly decreased from 74 to 55% in the treatment group, compared to a decrease of 76 to 74% in the control group. Ganopoly treatment also resulted in a significant decrease of blood pressure, whereas control group did not. The diastolic pressure was decreased by ≥10 mmHg in 22.5% patients receiving Ganopoly. The average blood pressure (systolic/diastolic, 142.5/96.4 mmHg) in this group was reduced to 135.1/92.8 mmHg after 12 weeks of treatment. Serum cholesterol levels decreased significantly after 12 weeks of Ganopoly therapy to the baseline values, whereas cholesterol levels remained unchanged in the control group. Ganopoly is well tolerated and appeared to be active in patients with CHD.

CITED BY
  1. Klupp Nerida L, Chang Dennis, Hawke Fiona, Kiat Hosen, Grant Suzanne J, Bensoussan Alan, Klupp Nerida L, Ganoderma lucidum for the treatment of cardiovascular risk factors, in Cochrane Database of Systematic Reviews, 2008. Crossref

  2. Klupp Nerida L., Kiat Hosen, Bensoussan Alan, Steiner Genevieve Z., Chang Dennis H., A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome, Scientific Reports, 6, 1, 2016. Crossref

  3. Wasser Solomon P., Medicinal Properties and Clinical Effects of Medicinal Mushrooms, in Edible and Medicinal Mushrooms, 2017. Crossref

  4. Zhang Jingsong, Liu Yanfang, Tang Qingjiu, Zhou Shuai, Feng Jie, Chen Hongyu, Polysaccharide of Ganoderma and Its Bioactivities, in Ganoderma and Health, 1181, 2019. Crossref

  5. Lee Hyeon A, Cho Jae-Han, Afinanisa Qonita, An Gi-Hong, Han Jae-Gu, Kang Hyo Jeung, Choi Seong Ho, Seong Hyun-A, Ganoderma lucidum Extract Reduces Insulin Resistance by Enhancing AMPK Activation in High-Fat Diet-Induced Obese Mice, Nutrients, 12, 11, 2020. Crossref

  6. Krittanawong Chayakrit, Isath Ameesh, Hahn Joshua, Wang Zhen, Fogg Sonya E., Bandyopadhyay Dhrubajyoti, Jneid Hani, Virani Salim S., Tang W.H. Wilson, Mushroom Consumption and Cardiovascular Health: A Systematic Review, The American Journal of Medicine, 134, 5, 2021. Crossref

  7. Du Qing, Cao Yuxin, Liu Chang, Lingzhi, An Overview, in The Lingzhi Mushroom Genome, 2021. Crossref

  8. Bös Dorothee, Mykotherapie bei Fettstoffwechselstörungen – wertvoller Beitrag von Vitalpilzen, Erfahrungsheilkunde, 70, 05, 2021. Crossref

  9. Liu Yadi, Lai Guoxiao, Guo Yinrui, Tang Xiaocui, Shuai Ou, Xie Yizhen, Wu Qingping, Chen Diling, Yuan Xujiang, Protective effect of Ganoderma lucidum spore extract in trimethylamine‐ N ‐oxide‐induced cardiac dysfunction in rats , Journal of Food Science, 86, 2, 2021. Crossref

  10. Chan Sze Wa, Tomlinson Brian, Chan Paul, Lam Christopher Wai Kei, The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk, Pharmaceutical Biology, 59, 1, 2021. Crossref

  11. Oke M. A., Afolabi F. J., Oyeleke O. O., Kilani T. A., Adeosun A. R., Olanbiwoninu A. A., Adebayo E. A., Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa, Frontiers in Pharmacology, 13, 2022. Crossref

  12. Klupp Nerida L, Chang Dennis, Hawke Fiona, Kiat Hosen, Cao Huijuan, Grant Suzanne J, Bensoussan Alan, Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors, Cochrane Database of Systematic Reviews, 2021, 9, 2015. Crossref

2855 Article views 41 Article downloads Metrics
2855 VIEWS 41 DOWNLOADS 12 Crossref CITATIONS Google
Scholar
CITATIONS

Articles with similar content:

A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis В International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Mutagenic Potential of Cypermethrin in Mouse Dominant Lethal Assay Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 3
Pankaj Taneja, Yogeshwer Shukla
Effect of Ling Zhi or Reishi Mushroom Ganoderma lucidum (W. Curt.: Fr.) P. Karst. Mycelium on Benzo[a]prene-Induced Early Alterations of the Respiratory Epithelium in the Hypercholesterolaemic Rats International Journal of Medicinal Mushrooms, Vol.9, 2007, issue 2
Suhaila Mohamed, Chow Chin Tong, Nor Aini B. Umar, Mohamed Mustapha Noordin, Yew Keong Choong
Fibrin Sealant Reduces Perioperative Blood Loss in Total Hip Replacement Journal of Long-Term Effects of Medical Implants, Vol.13, 2003, issue 5
Sandra G. Burks, Ross Crawford, Gwo-Jaw Wang, William D. Spotnitz, Charles A. Goldthwaite, Jr.
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain